Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder

International Journal of Adolescent Medicine and Health

Volumn 23, Issue 3, 2011, Pages 167-173

  Handen, Benjamin L ^a,b   Taylor, Johanna ^a,b   Tumuluru, Rameshwari ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

attention deficit hyperactivity disorder (ADHD); autism spectrum disorders; psychopharmacology

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; BETA ENDORPHIN; CLONIDINE; DONEPEZIL; GUANFACINE; MEMANTINE; METHYLPHENIDATE; NALTREXONE; RISPERIDONE; RIVASTIGMINE; VALPROATE SEMISODIUM;

ADD ON THERAPY; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; FATIGUE; HUMAN; HYPOTENSION; IRRITABILITY; NOCTURNAL ENURESIS; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CLINICAL TRIALS AS TOPIC; HUMANS; PROPYLAMINES;

EID: 80052701105     PISSN: 03340139     EISSN: 21910278     Source Type: Journal    
DOI: 10.1515/IJAMH.2011.039     Document Type: Review

References (53)

1. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 2007;40:180-7.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association, 2000.
3. Lecavalier, L. Behavior and emotional problems in young people with pervasive developmental disorders: Relevant prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 2006;36:1101-14.
4. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol 2005;15:671-81.
5. Pliszka SR. The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005;57:1385-90.
6. Aman MG. Stimulant drugs in the developmental disabilities revisited. J Dev Phys Disabil 1996;4:347-66.
7. Campbell M. Pharmacotherapy in early infantile autism. Biol Psychiatry 1975;10:399-423.
8. Campbell M, Cohen I. Treatment of infantile autism. Compr Ther 1978;4:33-7.
9. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: Safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J Child Adolesc Psychopharmacol 2004;14:207-18.
10. Quintana H, Birmaher B, Stedge D, Lennon S, Freed J. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995;25:283-94.
11. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245-55.
12. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ, et al. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:49-56.
13. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-74.
14. Garnock-Jones KP, Keating GM. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatric Drugs 2009;11:203-26.
15. Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15:325-30.
16. Troost PW, Althaus M, Lahuis BE, Buitelaar JK, Minderaa RB, et al. Neuropsychological effects of risperidone in children with pervasive developmental disorders: A blinded discontinuation study. J Child Adolesc Psychopharmacol 2006;16:561-73.
17. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16:599-610.
18. Swanson JM. School-based assessments and interventions for ADD students. Irvine, CA: KC Publishing, 1992.
19. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Mental Deficiency 1985;89:485-91.
20. Conners CK. Conners'Continuous Performance Test-II. North Tonawanda, NY: Multi-Health Systems, 2000.
21. Arnold LE, Aman MG, Cook A, Witwer A, Hall K, et al. Atomoxetine for hyperactivity in autistic spectrum disorders: Placebo-controlled crossover trial. J Am Acad Child Adolesc Psychiatry 2006;45:1196-205.
22. Werry JS, Aman MG. Practitioner's guide to psychoactive drugs for children and adolescents, 2nd ed. New York: Plenum Medical Book, 1999.
23. Poncin Y, Scahill L. Stimulants and nonstimulants in the treatment of hyperactivity in autism. In: Hollander E, Anagnostou E, editors. Clinical manual for the treatment of autism. Washington, DC: American Psychiatric Publishing, 2007:131-52.
24. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002; 58:527-36.
25. Jaselskis CA, Cook EH, Fletcher KE, Leventhal B. Clonidine treatment of hyperactivity and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;12:322-6.
26. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
27. Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004;14:233-41.
28. Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16:589-98.
29. Handen BL, Sahl R, Harden AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008;29:303-8.
30. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121:e73-84.
31. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:215-26.
32. McCracken JT, McGough J, Shah B, Cronin P, Hong D, et al. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21.
33. Shea S, Turgay A, Carrol A, Schulz M, Orlik H, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Am J Psychiatry 2004;161:2115-7.
34. Marcus RN, Owen R, Kamen L, Manos, G, McQuade RD, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48: 1110-9.
35. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001;57:1618-28.
36. King BH, Wright M, Snape M, Dourish CT. Case series: Amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. J Am Acad Child Adolesc Psychiatry 2001;40:654-7.
37. King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, et al. A double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40:658-65.
38. Chamberlain RS, Herman BH. A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism. Biol Psychiatry 1990;28:773-93.
39. Kolmen BK, Feldman H, Handen BL, Janosky JE. Naltrexone in young autistic children: A double blind placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995;34:223-31.
40. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: Replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997;36:1570-8.
41. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW. Lamotrigine therapy for autistic disorder: A randomized, double- blind, placebo-controlled trial. J Autism Dev Disord 2001; 31:175-81.
42. Hellings JA, Weckbaugh M, Nickel EJ, Cain S, Zarcone J, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:682-92.
43. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism. In: Bauman M, Kemper T, editors. The neurobiology of autism. Baltimore, MD: Johns Hopkins University Press, 1994:119-45.
44. Perry E, Lee M, Martin-Ruiz C, Court J, Volsen S, et al. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001;158:1058-66.
45. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 2002;12:237-42.
46. Chez MG, Buchanan TM, Becker M, Kessler J, Aimonovitch MC, et al. Donepezil hydrochloride: A double-blind study in autistic children. J Pediatric Neurol 2003;1:83-8.
47. Yoo HJ, Valdovinos HG, Williams DC. Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature. J Autism Dev Disord 2007;37:1883-901.
48. Handen BL, Johnson CR, McAuliffe-Bellin SJ, Hardan AO. Safety and efficacy of donepezil in children and adolescents with autism: Behavioral measures. Int J Adolesc Med Health 2010;2:125-34.
49. Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004;19:165-9.
50. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: A review of preclinical data. Neuropharmacology 1999;38:735-67.
51. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22:574-9.
52. Bangs ME, Tauscher-Wisniewsk S, Polzer J, Zhang, S, Acharya N, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47:209-18.
53. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: A retrospective cohort study of children, adolescents and young adults using the General Practice Research Database. Drug Saf 2009;32:1089-96.